Core Insights - Carlsmed, Inc. reported a revenue of $12.1 million for Q2 2025, marking a 99% year-over-year growth from $6.1 million in Q2 2024 [1][3] - The company anticipates full-year revenue to be between $45.5 million and $47.5 million, representing a growth of 67% to 75% compared to 2024 [4] Financial Performance - Gross profit for Q2 2025 was $8.9 million, up from $4.6 million in Q2 2024, with a gross margin of 73.4% compared to 75.0% in the prior year [3] - Operating expenses increased to $15.4 million in Q2 2025 from $10.9 million in Q2 2024, driven by higher sales and marketing costs [3] - Net loss for Q2 2025 was $6.8 million, slightly higher than the $6.3 million loss in Q2 2024 [3] Technology and Market Position - The growth in revenue was attributed to the increased adoption of the AI-enabled aprevo technology platform, which is recognized for improving patient outcomes compared to traditional devices [2] - Carlsmed successfully completed its first personalized cervical spine surgery using the aprevo platform in July 2025, with plans for a commercial launch in 2026 [2][3] Cash Position - As of June 30, 2025, Carlsmed had cash and cash equivalents of $33.5 million, bolstered by $93.5 million in net proceeds from its initial public offering in July 2025 [3]
Carlsmed® Reports Second Quarter 2025 Financial Results